A best evidence topic was written according to a structured protocol. The question addressed was: in surgically fit patients with biopsyproven asymptomatic pulmonary hamartoma, is surgical resection superior to conservative watchful waiting in terms of outcome. A total of 460 papers were identified using the reported search, of which 9 represented the best evidence to answer the clinical question. The authors, date, journal, country, study type, population, outcomes and key results are tabulated. Three studies were observational following up biopsy-proven asymptomatic pulmonary hamartoma with no resection for a mean period up to 5 years (where mentioned). No patients developed new symptoms or malignant transformation. One of the three studies considered tumour growth in patients with pulmonary hamartoma to be slow with a mean expansion in transverse diameter of 3.2 ± 2.6 mm per year. There were five sizable retrospective studies and one observational study for resection of pulmonary hamartoma. Three of the six studies showed no postoperative mortality but there was an association with major resection (lobectomy/pneumonectomy) ranging from 10 to 14%. There was no tumour recurrence during a long follow-up period in the three studies. One other study had a 4% postoperative mortality rate and a 1.8% postoperative lung cancer developing rate during a follow-up period of 61 months with a consequent recommendation against surgery in asymptomatic patients. In another study, there was a 2.6% recurrence rate after surgical resection during a follow-up period of 7.3 years whereas in the final observational study, 3 patients developed a malignant lung lesion during a follow-up period of 2-10 years after resection and in the same area from where the hamartoma was excised. In conclusion, we would recommend surveillance, rather than resection, of patients with biopsy-proven asymptomatic pulmonary hamartomas, since there is no evidence of malignant transformation during follow-up in any study. Resection is usually safe but a significant number of patients need a major resection (lobectomy or pneumonectomy, 10-14%) for clearance. Diagnosis can be achieved by a combination of radiological evidence and fine needle biopsy (sensitivity 85-90%). Therefore, resection should be reserved for symptomatic patients, or where the diagnosis remains in doubt.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol. This is fully described in ICVTS [1] . 
THREE-PART QUESTION

CLINICAL SCENARIO
A 54-year old male presents with an incidental finding of a mass measuring 3 cm in diameter discovered on a routine chest X-ray during a medical check-up. A computed tomography (CT)-guided biopsy confirms this to be a pulmonary hamartoma in the periphery of the right upper lobe. The patient is scheduled for a videoassisted thoracoscopic surgical resection. The patient questions if he can be managed conservatively without surgery. It is decided to look at the evidence on the topic to access if one policy is superior to the other.
SEARCH STRATEGY
A Medline and Korean med search from 1980 to February 2015 was performed using [pulmonary hamartoma OR lung hamartoma OR chondromatous hamartoma OR hamartochondroma OR adenochondroma OR mesenchymoma] AND (resection OR surveillance OR conservative). English language papers only, were included. 
SEARCH OUTCOME
Four hundred and sixty papers were found using the reported search. From these, nine papers were identified that provided the best evidence to answer the question. These are presented in Table 1 .
RESULTS
Lien et al.
[2] conducted a retrospective study over a 31-year period on 61 patients who had resection of their pulmonary hamartoma out of which 41 were asymptomatic. There were no operative related deaths and a mean follow-up period of 8.9 years revealed no tumour recurrence. The authors concluded that resection of pulmonary hamartomas was safe with good prognosis. Caylak et al. [3] conducted a retrospective analysis on 20 patients who had a pulmonary hamartoma resected between 2003 and 2007. Seventeen were asymptomatic. Fifteen had calcification on CT criteria. Eighteen patients required a thoracotomy. There were no mortalities and two acceptable morbidities in this series. There was no tumour recurrence on a median follow-up period of 32 months. The authors concluded that resection of pulmonary hamartomas can be done safely with a good long-term outcome.
Guo et al. [4] reviewed their experience with resection of pulmonary hamartomas over a 20-year period. Thirty-nine cases were included. Nine were asymptomatic. Three patients needed a lobectomy and 1 patient needed a pneumonectomy (4/39 = 10%). There was no operative mortality and 2 cases developed morbidities. Thirty-eight cases were followed up for a mean period of 7.3 years. There was one recurrence (2.6%) and no malignant transformation in their series. The authors concluded that resection of pulmonary hamartoma is safe with a good long-term outcome.
Lee et al. [5] performed a retrospective review of 29 patients with pulmonary hamartomas over a 9-year period. Seventeen were asymptomatic. Twenty-six patients (89.6%) underwent resection. Three patients needed a lobectomy and 1 needed a pneumonectomy (4/29 = 14%). There was no operative mortality and no patient suffered from recurrences for a mean follow-up period of 19.6 months. The authors concluded that resection of pulmonary hamartomas is safe with good prognosis.
Gjevre et al. [6] reviewed their 17-year experience with 215 patients with pulmonary hamartomas out of which 208 were asymptomatic. In the group that had resection, there were 8 postoperative deaths (4%) and 3 patients developed malignancy during a mean follow-up period of 61 months. This is explainable as 63 patients (29.3%) in their series had concurrent neoplasms 
BEST EVIDENCE TOPIC
H. Elsayed et al. / Interactive CardioVascular and Thoracic Surgerybeing referred for treatment of lung cancer and a hamartoma was resected on an incidental basis. The authors concluded that due to high rate of postoperative mortality in their series, surgical resection for isolated pulmonary hamartoma should be performed only when the lesion is large, there is a rapid increase in the size of the lesion, or when the patient is symptomatic. Hansen et al. [7] was the first study actually comparing resection of pulmonary hamartoma with surveillance. They conducted a study on 89 patients with pulmonary hamartoma. Forty patients had a needle biopsy with a sensitivity of 85%. Seventy-five patients (84%) underwent surgical resection whereas 15 patients (16%) had only surveillance and 1 patient proceeded with surgery due to tumour expansion. Tumour growth was recorded in the rest of the 14 patients with the mean expansion in transverse diameter of 3.2 ± 2.6 mm per year during an average observation time of 4.1 years (range 1-20 years). The authors concluded that most pulmonary hamartomas are non-expanding or slowly growing neoplasms, and suggested that operation is necessary to 50 years of age (with longer life spans) and in patients with pulmonary symptoms.
Karasik et al. [8] performed an observational study on 52 patients with resected asymptomatic pulmonary hamartoma over a 15-year period. There was no operative mortality but 3 patients developed a malignant lung lesion during a follow-up period of 2-10 years and in the same area from where the hamartoma was excised raising the concern that the development of malignancy was related to surgical manipulation. The coincidental nature of developing lung cancer in these 3 patients cannot be excluded but the authors concluded that there is a 6.3 times more risk of developing lung cancer in hamartoma patients than the age-sex-ethnic adjusted rate expected for the Israeli population (P = 0.0016).
Hamper et al. [9] had 14 patients presenting with asymptomatic peripheral pulmonary hamartoma. All 14 patients had a transthoracic needle aspiration biopsy (TNAB) which confirmed the diagnosis in 12 patients (86%). Two patients required a surgical biopsy for the confirmation of diagnosis. One of the 12 patients with confirmed diagnosis with TNAB proceeded with surgical resection which further confirmed the diagnosis and the rest of the 11 patients were followed up (no mention of follow-up period) and developed no complications. The authors concluded that it is reasonable to follow-up patients with confirmed pulmonary hamartoma.
Sinner [10] was the most recent study comparing resection of hamartomas with surveillance. They analysed 61 patients with asymptomatic needle biopsy-proven peripheral pulmonary hamartoma. Forty-one patients had a 5-year follow-up (longest follow-up period for non-resected lesions in all studies) and developed no new symptoms or malignant transformation. Twenty patients had a lung sparing resection of their hamartoma. Postoperative diagnosis was similar in 18 patients (90% accuracy) whereas 2 patients were found to have a benign fibroma and a chemodectoma. The study concluded that it is reasonable to follow-up pulmonary hamartomas since follow-up for a long period revealed no malignant transformation and that needle biopsy of hamartoma is relatively sensitive in establishing diagnosis.
CLINICAL BOTTOM LINE
We would recommend surveillance, rather than resection, of patients with biopsy-proven asymptomatic pulmonary hamartomas since there is no evidence of malignant transformation during follow-up in any study. Resection is usually safe but a significant number of patients need a major resection (lobectomy or pneumonectomy, 10-14%) for clearance. Diagnosis can be achieved by a combination of radiological evidence and fine needle biopsy (sensitivity 85-90%). Therefore, resection should be reserved for symptomatic patients, or where the diagnosis remains in doubt.
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